3rd Glioblastoma Drug Development Summit
Start Date: 2022-01-18
End Date: 2022-01-20
Time: 8:00 am to 5:40 pm
Together we will increase the length and quality of patient survival from diagnosis.
The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma.
Through investigating the clinical implementation of diverse mechanisms of action, including, DNA damage repair, immunotherapy, oncolytic viruses, cholesterol metabolism, PARP inhibitors and more, we strive to address the urgent need for novel and much improved treatments for this devastating disease.
Tackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials.
With a huge unmet medical need for effective treatments and too many clinical failures to overcome, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives.
Join us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients
Speakers:Petra Hamerlik Associate Research Director AstraZeneca, Ranjit Bindra Professor, Therapeutic Radiology Yale University School of Medicine, Patrick Wen Director Neuro- Oncology Dana Farber Cancer Institute, Bob Dillman CMO AIVITA Biomedical, Heinz Lubenau CEO VAXIMM, Mike Goguen Founder & Managing Partner Two Bear Capital, Suzanne Forry Program Director, Preclinical Therapeutics Grants Branch National Cancer Institute, Jim Beach COO Bexion Pharmaceuticals, Kirk Tanner CSO National Brain Tumor Society, Joao Sexias CEO Targtex, Adilia Hormigo Professor of Neurology The Tisch Cancer Institute Combination Workshop, John De Groot Professor Neuro- Oncology MD Anderson Cancer Center, Klaus Veitinger Venture Partner OrbiMed Advisors, Marnix Bosch CTO NorthWest Biotherapeutics, Steve Kay Professor of Neurology Keck School of Medicine, Alex Tendler CTO ExoProTher Medical, Sheila Singh Professor of Surgery Mc Master University, Rifaquat Rahman Radiation Oncology Dana Farber Cancer Institute, Christophe Queva CSO Oncorus, Josh Rubin Neuro-Oncologist Washington University, Jeffrey Skolnik VP Clinical Development Inovio, Amy Heimburger Neurological Surgery Northwestern Medical Group, Becky Bish Head of Discovery & Preclinical Research The Mark Foundation, Mariella Filbin Pediatric Oncologist Dana Farber Cancer Institute, James Garner CEO Kazia Therapeutics, Susan Chang Professor Neurological Surgery UCSF Weill Institute for Neurosciences, Michael Lim Professor & Chair Department of Neuro Surgery Stanford University School of Medicine, David Louis Pathologist-in- Chief Massachusetts General Hospital, Justin Lathia Vice Chair Cleveland Clinic, Neil White Investment Manager Health Emerson Collective, Saiid Zarrabian President & CEO Kintara Therapeutics, Dennis Brown CSO Kintara Therapeutics, Dennis Brown CSO Kintara Therapeutics, Shwetal Mehta COO Ivy Brain Tumor Center, Ben Ellingson Professor – Radiology, Biomedical Physics & Bioengineering UCLA
Conference Only (1st Release - pay by September 24) USD 1299.00,
Conference Only (2nd Release - pay by October 22) USD 1499.00,
Conference Only (3rd Release - pay by November 19) USD 1699.00,
Conference Only (4th Release - pay by December 17) USD 1899.00,
Conference Only (Standard Rate) USD 2099.00,
Conference Only (On the Door) USD 2199.00
Click the link for registration or ticketing information:
Organized by : Hanson Wade Tel : +4402031418700